Meeting
2017 Gastrointestinal Cancers Symposium
Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.
Authors
Jonathan R. Strosberg
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Jonathan R. Strosberg , Edward M. Wolin , Beth Chasen , Matthew H. Kulke , David L Bushnell Jr., Martyn E. Caplin , Richard P. Baum , Pamela L. Kunz , Timothy J. Hobday , Andrew Eugene Hendifar , Kjell E. Oberg , Maribel Lopera Sierra , Dik J. Kwekkeboom , Philippe B. Ruszniewski , Eric Krenning
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01578239
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 348)
DOI
10.1200/JCO.2017.35.4_suppl.348
Abstract #
348
Poster Bd #
F18
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors.
First Author: Jonathan R. Strosberg
Poster
2016 Gastrointestinal Cancers Symposium
NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate.
First Author: Jonathan R. Strosberg
Poster
2012 Gastrointestinal Cancers Symposium
Effect of octreotide LAR on quality of life of 93 Hungarian patients with neuroendocrine tumors.
First Author: Tibor Gyökeres
Poster
2021 ASCO Annual Meeting
Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.
First Author: Jonathan R. Strosberg